JPRN-UMIN000006123已完成1 期
Phase I study of Gemcitabine, Cisplatin and S-1 for advanced biliary tract cancer. - Phase I study of Gemcitabine, Cisplatin and S-1 for advanced biliary tract cancer. (GPS-P1 study)
Tsukuba University Hospital, Division of Gastroenterology0 个研究点目标入组 12 人开始时间: 2011年8月17日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 12
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1.With a history of severe drug allergy 2.Active infection 3.Sever complication 4.With uncontrollable diabetes mellitus (HbA1C >=8.0%) 5.With steroid 6.With interstitial pneumonia or pulmonary fibrosis 7.With severe pleural effusion or ascites 8.Active double cancer 9.Patients who are pregnant or lactating, or have an intention to get pregnant 10.Inadequate physical condition, as diagnosed by primary physician
研究者
相似试验
招募中
1 期
Phase 1 study of Gemcitabine, Cisplatin and S-1 combination chemotherapy in patients with advanced biliary tract cancerJPRN-UMIN000009536Kitasato University School of Medicine Department of Gastroenterology Medicine12
尚未招募
Unknown
Phase III study of gemcitabine, cisplatin plus S-1 combination therapy versus gemcitabine, cisplatin plus immune checkpoint inhibitor combination therapy in advanced biliary tract cancer.advanced biliary tract cancerJPRN-UMIN000051689Yamaguchi University460
已完成
1 期
Phase I/II study of gemcitabine/cisplatin/S-1(GCS) combination therapy for patients with advanced biliary tract cancerPatients with advanced biliary tract cancer that was not amenable to potentially curative surgery or that had recurred after surgeryJPRN-UMIN000004468Kansai Hepatobiliary Oncology Group55
招募中
2 期
A Phase II study of Gemcitabine, Cisplatin and Bevacizumab for the patients with first recurrent and refractory ovarian clear cell carcinomaJPRN-UMIN000051087Kansai Clinical Oncology Group(KCOG)28
尚未招募
不适用
Phase I study of gemcitabine and carboplatin plus sorafenib in patients with advanced solid tumorsadvanced solid tumors10027655CancerNL-OMON31053Antoni van Leeuwenhoek Ziekenhuis28